ABSTRACT
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China.It has high malignancy,strong invasion and metastasis,and a poor prognosis.It seriously threatens the life and health of people.With the development of modem medical technology,the treatment of HCC has developed into a comprehensive treatment mode based on surgical resection.At present,surgery is still the best cure for liver cancer.The treatment plan should be formulated according to different individuals,such as surgical treatment,ablation,embolization,chemotherapy,molecular targeted therapy,immunotherapy treatment and sequential application of that comprehensive treatment,to improve the overall efficacy of HCC and prolong the survival period and improve the quality of life of patients.The present situation of comprehensive treatment of HCC was discussed in this paper.
ABSTRACT
Translational medicine is characterized by its close association with precision medicine in the field of colorectal cancer.In particular,the studies of life histology promote the prevention and treatment of colorectal cancer entered the stage of precision medicine.Accurate molecular typing of colorectal cancer has been used to guide clinical practice is an important breakthrough in the field of colorectal cancer translational medicine in recent years,and its clinical value has been verified.As an important tool for the effective integration of clinical data and life histology data,the biomedical big data platform is expected to contribute to the continued breakthrough of translational medicine in precision molecular typing.New treatment methods,such as liquid biopsy technology with non-invasive,flexible features can be dynamically detected as soon as possible to find the state of somatic mutations.Among them,circulating tumor DNA has a good detection sensitivity and specificity,highlighting the value of early recurrence monitoring.In addition,new therapeutic strategies,such as immunological checkpoints and chimeric antigen receptor genetically modified T-cell therapy,are under intense study in the field of colorectal cancer.Based on the biomedical big data analysis in the context of the precise molecular typing,dynamic liquid biopsy monitoring technology,new immunotherapy and other fields will be the future of colorectal cancer translational medicine research hot and breakthrough direction.
ABSTRACT
Gastric cancer is one of the most common malignant digestive tumors globally.The comprehensive treatment based on surgery of gastric cancer can not satisfy the purpose to reduce morbidity and mortality.In recent years,translational medicine has emerged with the rapid development of basic medical research,such as molecular biology,and the change of medical patterns.The core of translational medicine is to establish a fast conversion channel between basic research and clinical applications which could translate basic research results into theories,technologies and products for clinical practice.In the present paper,the research progress of translational medicine in the diagnosis and treatment of gastric cancer will be summarized,and the role of translational medicine for precise treatment of gastric cancer will be discussed.
ABSTRACT
Immune associated ophthalmopathy ranks as one of the major causes of visual handicap in adults, including ocular tumor, uveitis, corneal transplantation rejection, thyroid associated ophthalmopathy, and so on. These conditions are difficult to therapy, bad prognosis, and are an urgent ophthalmic clinical problems to be solved. Immunotherapies have been playing an important role in the comprehensive therapy for immune associated ophthalmopathy. This article reviewed on this study.
ABSTRACT
There were many progressions of hepatocellular carcinoma (HCC) in the 2017 annual meeting of the American Society of Clinical Oncology (ASCO).(1) Sorafenib has been at the heart of treatment for advanced HCC,meanwhile,it has been confirmed to effectively prolong the life time of patients and improve the clinical efficacies combined with other therapies.A variety of molecular and clinical indicators also help screening out peoples.(2) New molecular targeted drugs have sprung up,and Lenvatinib (multiple receptor tyrosine kinases inhibitor) is expected to become the next first-line drug.The second-line Regorafenib has obtained supporting evidence from evidencebased medicine,and a combination therapy of Sorafenib and Regorafenib promises to be a new model of targeted therapy for HCC.However,the phase Ⅲ study (METIV-HCC) of which Tivatinib (ARQ 197) becomes the second-line drug for HCC has failed.(3) Immunization therapy remains a hotspot for HCC.The monoclonal antibodies of immunological checkpoint and adoptive immunotherapy have better safety and clinical efficacy.(4) Primary lesions resection of HCC and drug control of metastatic lesions are expected to be the therapy model for metastatic HCC.The liver transplantation for primary HCC will be further developed.(5) The combination and sequential application of multiple therapies will become an inevitable choice,and efficacy of stereotactic body radiation therapy is expected.The combination and sequential application of transcatheter arterial chemoembolization (TACE) and other therapies is still a main therapy for unresectable HCC.(6) The new predictors and models of prognosis have been popping up,nevertheless,its therapy effects should be further proven.
ABSTRACT
The evaluation of Aslem efficacy on post- operative survival duration of 164 patients with primary liver cancer treated in Viet Duc Hospital during 1991-2000 year period showed the supporting effect of Aslem after surgery, it improved dramatically the post operative survival duration of patients, especially in the group of removing liver lesions in combining with aslem in yield directly into the tumor